Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 57 entries
View as:

Mantel Cell Lymphoma Efficacy of Rituximab Maintenance

Phase: N/A Priority: Normal
NCT ID: NCT00921414 Org: User:
Start: 09/30/08 End: 02/28/17 Due: 02/28/18

Epidemiological Study of a Prospective Cohort of Patients Aged 60 and Over Managed for Acute Myeloid Leukemia (AML) and Receiving Intensive Induction Therapy

Phase: N/A Priority: Normal
NCT ID: NCT06891144 Org: User:
Start: 01/06/15 End: 01/06/31 Due: 01/06/32

Bendamustine in Patients With Refractory or Relapsed T-cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00959686 Org: User:
Start: 09/30/09 End: 02/28/13 Due: 02/28/14

Phase II Study Evaluating the Efficacy and Safety of the Combination of Tagraxofusp and Venetoclax in Treatment-naive Blastic Plasmacytoid Dendritic Cell Neoplasm Patients

Phase: N/A Priority: Normal
NCT ID: NCT07007052 Org: User:
Start: 09/30/25 End: 09/30/31 Due: 09/30/32

Study Evaluating the Efficacy and Tolerance of a Zanubrutinib and BGB-11417 Combination in Patients Previously Treated for Waldenström Macroglobulinemia

Phase: N/A Priority: Normal
NCT ID: NCT06547866 Org: User:
Start: 06/01/25 End: 12/31/31 Due: 12/31/32

Evaluation of Treatment by Glofitamab in Combination With Rituximab or Obinutuzumab Plus CHOP in Patients With RIchter Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT06186648 Org: User:
Start: 03/21/24 End: 03/01/27 Due: 03/01/28

Results From a French Temporary Utilization Authorization of First-line Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Chemotherapy (IC), Treated With Venetoclax Azacitidine

Phase: N/A Priority: Normal
NCT ID: NCT06263387 Org: User:
Start: 07/04/24 End: 03/30/25 Due: 03/30/26

Multicentric Registry of Patients With Acute Leukemia Infected by COVID-19

Phase: N/A Priority: Normal
NCT ID: NCT04452604 Org: User:
Start: 09/11/20 End: 07/07/21 Due: 07/07/22

Venetoclax + Cytarabine Versus Idarubicin + Cytarabine : Efficacity Assessment as Post-remission Therapy to Elderly Patients With Acute Myeloid Leukemia in First Remission

Phase: N/A Priority: Normal
NCT ID: NCT04968015 Org: User:
Start: 05/25/22 End: 01/31/29 Due: 01/31/30

Efficacity of Idelalisib and Obinutuzumab in Patient With Relapsed Refractory Waldenstrom's Macroglobulinemia

Phase: N/A Priority: Normal
NCT ID: NCT02962401 Org: User:
Start: 03/07/17 End: 04/13/23 Due: 04/13/24

Pilot Study Efficacy and Tolerance Fish Oil Emulsion Daunorubicin and Cytarabine Treatment of AML Younger Patients

Phase: N/A Priority: Normal
NCT ID: NCT01999413 Org: User:
Start: 11/30/13 End: 04/30/18 Due: 04/30/19

Study Impact on Outcome of Eltrombopag in Elderly Patients with Acute Myeloid Leukemia Receiving Induction Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT03603795 Org: User:
Start: 10/11/18 End: 07/30/26 Due: 07/30/27

STop and Restart Acalabrutinib In fRail Patients With Previously Untreated Chronic Lymphocytic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT04963946 Org: User:
Start: 10/18/21 End: 08/01/28 Due: 08/01/29

A Non-interventional Ambispective Real-world Cohort of rEfractory and reLapsed (R/R) FLT3 Mutated Acute MyEloid Leukemia (AML) Patients Treated With Gilteritinib in FrANCE

Phase: N/A Priority: Normal
NCT ID: NCT05193448 Org: User:
Start: 07/05/21 End: 01/31/22 Due: 01/31/23

Study of 90Y-DOTA-hLL2 as a Consolidation Therapy After R-CHOP in Patients With Diffuse Large B-cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00906841 Org: User:
Start: 10/31/07 End: 04/30/18 Due: 04/30/19

GM-CSF and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00893477 Org: User:
Start: 03/31/09 End: - Due: -

Prognostic Analyses on a Validation Series of Patients with Waldenström's Disease

Phase: N/A Priority: Normal
NCT ID: NCT05911802 Org: User:
Start: 08/11/23 End: 06/15/30 Due: 06/15/31

Treatment of Aggressive Localized Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00841945 Org: User:
Start: 04/30/05 End: 02/28/17 Due: 02/28/18

Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage a

Phase: N/A Priority: Normal
NCT ID: NCT03766763 Org: User:
Start: 05/22/19 End: 04/24/30 Due: 04/24/31

Tolerance and Resistance to Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL

Phase: N/A Priority: Normal
NCT ID: NCT03502876 Org: User:
Start: 11/02/17 End: 12/31/19 Due: 12/31/20

Evaluation of CPX-351 Monotherapy in Acute Myeloid Leukemia Secondary to Myeloproliferative Neoplasm

Phase: N/A Priority: Normal
NCT ID: NCT04992949 Org: User:
Start: 03/23/22 End: 12/04/23 Due: 12/04/24

Observatory of Patients With Chronic Lymphocytic Leukemia / Lymphocytic Lymphoma or Waldenstrom Disease Infected With COVID-19

Phase: N/A Priority: Normal
NCT ID: NCT04391946 Org: User:
Start: 03/14/20 End: 03/10/23 Due: 03/10/24

Observatory of Prolymphocytic Leukemia T

Phase: N/A Priority: Normal
NCT ID: NCT04411043 Org: User:
Start: 07/01/20 End: 06/30/25 Due: 06/30/26

Lomustine and Intermediate Dose Cytarabine in Older Patients With AML

Phase: N/A Priority: Normal
NCT ID: NCT00480064 Org: User:
Start: 07/31/95 End: 05/31/07 Due: 05/31/08

Intensified Rituimab Prephase Before FCR in Untreated B-CLL

Phase: N/A Priority: Normal
NCT ID: NCT01370772 Org: User:
Start: 05/31/11 End: 03/31/16 Due: 03/31/17